AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Zinforo.
Zinforo is an antibiotic for the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia.
The positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union.
Click below for release from AstraZeneca.
